Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing advanced antibody complement therapeutics to treat severe autoimmune diseases. The company operates in the biopharmaceutical market, targeting neuromuscular indications such as generalized Myasthenia Gravis, Multifocal Motor Neuropathy, and Chronic Inflammatory Demyelinating Polyneuropathy. Dianthus Therapeutics' lead product, DNTH103, is a potent monoclonal antibody designed to selectively inhibit the active form of the C1s protein in the classical complement pathway. This targeted approach aims to reduce the risk of infections while providing a more convenient treatment option through subcutaneous, self-administered injections that can be dosed as infrequently as once every two weeks. The company generates revenue through the development and potential commercialization of its therapeutic candidates, with a business model centered on advancing its clinical programs through various phases of trials and regulatory approvals. Dianthus Therapeutics serves patients with severe autoimmune conditions, aiming to establish new standards of care in the neuromuscular disease space.

Keywords: antibody therapeutics, autoimmune diseases, clinical-stage, biotechnology, neuromuscular, DNTH103, monoclonal antibody, C1s protein, subcutaneous injection, biopharmaceutical.